190 related articles for article (PubMed ID: 37699041)
21. PERFUSE: Non-Interventional Cohort Study of Patients Receiving Infliximab Biosimilar SB2: Results in Pediatric Patients.
Martinez-Vinson C; Lemoine A; Bouhnik Y; Braithwaite B; Fohlen-Weill A; Addison J
J Pediatr Gastroenterol Nutr; 2023 Apr; 76(4):451-459. PubMed ID: 36729422
[TBL] [Abstract][Full Text] [Related]
22. Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Ferrante M; Jordi Guardiola ; Jahnsen J; Louis E; Lukáš M; Reinisch W; Roblin X; Smith PJ; Kwon T; Kim J; Yoon S; Kim DH; Atreya R
BMC Gastroenterol; 2024 Mar; 24(1):121. PubMed ID: 38539103
[TBL] [Abstract][Full Text] [Related]
23. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
[TBL] [Abstract][Full Text] [Related]
24. Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort.
Gros B; Plevris N; Constantine-Cooke N; Lyons M; O'Hare C; Noble C; Arnott ID; Jones GR; Lees CW; Derikx LAAP
United European Gastroenterol J; 2023 Mar; 11(2):179-188. PubMed ID: 36802176
[TBL] [Abstract][Full Text] [Related]
25. One-Year Clinical Outcomes of Subcutaneous Infliximab Maintenance Therapy Compared With Intravenous Infliximab Maintenance Therapy in Patients With Inflammatory Bowel Disease: A Prospective Cohort Study.
Hong SN; Hye Song J; Jin Kim S; Ha Park Y; Wan Choi C; Eun Kim J; Ran Kim E; Kyung Chang D; Kim YH
Inflamm Bowel Dis; 2024 Apr; 30(4):517-528. PubMed ID: 37260346
[TBL] [Abstract][Full Text] [Related]
26. An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease.
Ebada MA; Elmatboly AM; Ali AS; Ibrahim AM; Fayed N; Faisal AF; Alkanj S
Int J Colorectal Dis; 2019 Oct; 34(10):1633-1652. PubMed ID: 31492986
[TBL] [Abstract][Full Text] [Related]
27. Biosimilar infliximab in paediatric inflammatory bowel disease: Efficacy, immunogenicity and safety.
Dipasquale V; Romano C
J Clin Pharm Ther; 2020 Dec; 45(6):1228-1234. PubMed ID: 32743840
[TBL] [Abstract][Full Text] [Related]
28. Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb.
Bhat S; Altajar S; Shankar D; Zahorian T; Robert R; Qazi T; Shah B; Farraye FA
J Manag Care Spec Pharm; 2020 Apr; 26(4):410-416. PubMed ID: 32223602
[TBL] [Abstract][Full Text] [Related]
29. Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers.
Tursi A; Mocci G; Faggiani R; Allegretta L; Valle ND; Forti G; Franceschi M; Ferronato A; Gallina S; Larussa T; Luzza F; Lorenzetti R; Penna A; Rodino S; Sebkova L; Lauria A; Piergallini S; Pranzo G; Ricciardelli C; Zampaletta C; Elisei W; Picchio M
Ann Gastroenterol; 2019; 32(4):392-399. PubMed ID: 31263362
[TBL] [Abstract][Full Text] [Related]
30. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
Avila-Ribeiro P; Fiorino G; Danese S
Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
Smith PJ; Critchley L; Storey D; Gregg B; Stenson J; Kneebone A; Rimmer T; Burke S; Hussain S; Yi Teoh W; Vazeille S; Serna S; Steel A; Derbyshire E; Collins P; Dibb M; Flanagan P; Probert C; Verma AM; Subramanian S
J Crohns Colitis; 2022 Sep; 16(9):1436-1446. PubMed ID: 35390141
[TBL] [Abstract][Full Text] [Related]
32. A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease.
Vahabnezhad E; Rabizadeh S; Dubinsky MC
Inflamm Bowel Dis; 2014 Apr; 20(4):606-13. PubMed ID: 24552827
[TBL] [Abstract][Full Text] [Related]
33. Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan.
Sagami S; Nishikawa K; Yamada F; Suzuki Y; Watanabe M; Hibi T
J Gastroenterol Hepatol; 2021 Aug; 36(8):2091-2100. PubMed ID: 33450057
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a real‑life experience in IBD primary centers.
Tursi A; Allegretta L; Chiri S; Della Valle N; Elisei W; Forti G; Lorenzetti R; Mocci G; Penna A; Pranzo G; Ricciardelli C; Picchio M
Minerva Gastroenterol Dietol; 2017 Dec; 63(4):313-318. PubMed ID: 28293938
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
Paul S; Del Tedesco E; Marotte H; Rinaudo-Gaujous M; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Roblin X
Inflamm Bowel Dis; 2013 Nov; 19(12):2568-76. PubMed ID: 24013361
[TBL] [Abstract][Full Text] [Related]
36. Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies.
Takeuchi T; Nishikawa K; Yamada F; Morita A; Ohtsuki M; Suzuki Y; Watanabe M; Yamanaka H; Hibi T
Drug Saf; 2023 Oct; 46(10):991-1005. PubMed ID: 37700154
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade.
Ilias A; Szanto K; Gonczi L; Kurti Z; Golovics PA; Farkas K; Schafer E; Szepes Z; Szalay B; Vincze A; Szamosi T; Molnar T; Lakatos PL
Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2506-2513.e2. PubMed ID: 30630103
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.
Gecse KB; Lovász BD; Farkas K; Banai J; Bene L; Gasztonyi B; Golovics PA; Kristóf T; Lakatos L; Csontos ÁA; Juhász M; Nagy F; Palatka K; Papp M; Patai Á; Lakner L; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Szalay B; Molnár T; Lakatos PL
J Crohns Colitis; 2016 Feb; 10(2):133-40. PubMed ID: 26661272
[TBL] [Abstract][Full Text] [Related]
39. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
[TBL] [Abstract][Full Text] [Related]
40. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
Eberl A; Huoponen S; Pahikkala T; Blom M; Arkkila P; Sipponen T
Scand J Gastroenterol; 2017 Dec; 52(12):1348-1353. PubMed ID: 28838273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
